Global Inflammatory Bowel Diseases (Ibd) Drug Market Forecast 2018-2028

 
 
logo
logo
 
Spread the Word
Listed Under

Tags:
Inflammatory Bowel Disease
Treating Lower Gut Disorders
Biosimilar Drug

Industry:
Business

Location:
London City - London, Greater - England

Subject:
Reports

LONDON - June 11, 2018 - PRLog -- Visiongain' (https://www.visiongain.com/) has launched a new pharma report Global Inflammatory Bowel Diseases (IBD) Drugs Market Forecast (https://www.visiongain.com/Report/2208/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Market-Forecast-2018-2028) 2018-2028: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis

There appear to be a marked variation in the prevalence rates of IBD. Crohn's disease and ulcerative colitis are much more common in developed countries than developing ones. One of the explanations is that there may be one or more environmental factors that increase the risk of IBD, which are presumably associated with Western diets and other lifestyle factors. The incidence rate of IBD appears to have stabilised in the West. In developing countries however, the number of new cases is growing annually. This may be due to Westernisation, changes in hygiene practices or more awareness of the disease. In any case, it seems likely that incidence and prevalence of IBD will increase in many countries around the world. As a consequence, demand for IBD drugs will rise (https://www.visiongain.com/Report/2208/Global-Inflammator...).

The lead analyst of the report commented "The inflammatory bowel diseases (IBD) drugs market will continue to be driven by rising disease incidence and more-effective non-invasive diagnosis. The IBD therapies market contains a diverse range of drugs, including biologics, which stimulate its revenue value and expand the market. Also, the incidence of IBD in emerging national markets is expected to rise as those countries become more developed."

Leading companies featured in the report include AbbVie, Janssen, Allergan, Shire, Takeda, Johnson & Johnson, UCB, Valeant, Astellas, Celgene, Takeda.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain (https://www.visiongain.com/) is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain (https://www.visiongain.com/) produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain (https://www.visiongain.com/) publishes reports produced by analysts who are qualified experts in their field. Visiongain (https://www.visiongain.com/) has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Contact
Sara Peerun
***@visiongain.com
End
Source:
Email:***@visiongain.com Email Verified
Tags:Inflammatory Bowel Disease, Treating Lower Gut Disorders, Biosimilar Drug
Industry:Business
Location:London City - London, Greater - England
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Visiongain PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share